Her2-low/ HRR proficient early triple negative breast cancer is characterized by good prognosis

被引：0
|
作者：
Pellegrino, B. [1 ]
Tornali, C. [2 ]
Lazzarin, A. [3 ]
Cotelli, B. [2 ]
Ingallinella, A. [2 ]
Campanini, N. [4 ]
Tommasi, C. [5 ]
Coriano, M. [6 ]
Serra, O. [7 ]
Michiara, M. [8 ]
Boggiani, D. [9 ]
Schirone, A. [10 ]
Casarini, C. [11 ]
Cretella, E. [12 ]
Zoppoli, G. [13 ,14 ]
Lambertini, M. [15 ]
Botosso, M. [16 ]
Cortesi, L. [17 ]
Silini, E. M. [18 ]
Musolino, A. [19 ]
机构：
[1] Osped Maggiore Parma, Oncol Dept, Parma, Italy
[2] Univ Parma, Oncol, Parma, Italy
[3] Univ Parma, Med Oncol Dept, Parma, Italy
[4] Univ Parma, Fac Med & Chirurg, Pathol, Parma, Italy
[5] Univ Parma, Fac Med & Chirurg, Med Oncol & Breast Unit, Parma, Italy
[6] Azienda Osped Univ Parma, Oncol, Parma, Italy
[7] Univ Parma, Fac Med & Chirurg, Oncol, Parma, Italy
[8] Osped Maggiore Parma, Oncol, Parma, Italy
[9] Univ Hosp Parma, Oncol, Parma, Italy
[10] Arcispedale SantAnna AOU Ferrara, Med, Ferrara, Italy
[11] Nuovo Osped Sassuolo, Oncol, Sassuolo, Italy
[12] Osped Cent Bolzano ASDAA SABES, Oncol Dept, Bolzano, Italy
[13] Univ Genoa, Dept Internal Med, Genoa, GE, Italy
[14] Osped Policlin San Martino IRCCS, DiMI, Genoa, GE, Italy
[15] IRCCS AOU San Martino, IST Ist Nazl Ric Canc, Oncol, Genoa, Italy
[16] IOV Ist Oncol Veneto IRCCS, Oncol, Padua, Italy
[17] Azienda Osped Univ Policlin Modena, Haematol & Oncol Dept, Modena, Italy
[18] Univ Parma, Pathol, Parma, Italy
[19] Univ Parma, Fac Med & Chirurg, Dept Med, Parma, Italy
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.212
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
269P
引用
收藏
页码：S328 / S329
页数：2
相关论文
共 50 条
  • [41] HER2-low breast cancer: where are we?
    Molinelli, Chiara
    Jacobs, Flavia
    Marchio, Caterina
    Pitto, Francesca
    Cosso, Maurizio
    Spinaci, Stefano
    de Azambuja, Evandro
    Schettini, Francesco
    Agostinetto, Elisa
    Lambertini, Matteo
    BREAST CARE, 2022, 17 (06) : 533 - 544
  • [42] Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low
    Xi′e Hu
    Ping Yang
    Songhao Chen
    Gang Wei
    Lijuan Yuan
    Zhenyu Yang
    Li Gong
    Li He
    Lin Yang
    Shujia Peng
    Yanming Dong
    Xianli He
    Guoqiang Bao
    Breast Cancer Research, 25
  • [43] The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan
    Schreiber, Anna R.
    O'Bryant, Cindy L.
    Kabos, Peter
    Diamond, Jennifer R.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (10) : 1061 - 1069
  • [44] Clinicopathological Characteristics and Prognosis of HER2-Low Early-Stage Breast Cancer: A Single-Institution Experience
    Xu, Hangcheng
    Han, Yiqun
    Wu, Yun
    Wang, Yan
    Li, Qing
    Zhang, Pin
    Yuan, Peng
    Luo, Yang
    Fan, Ying
    Chen, Shanshan
    Cai, Ruigang
    Li, Qiao
    Ma, Fei
    Xu, Binghe
    Wang, Jiayu
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [45] Epidemiology and Prognosis of HER2-Low Breast Cancer (BC) in the National Cancer Data Base (NCDB)
    Peiffer, Daniel
    Howard, Frederick M.
    Chen, Nan
    Hahn, Olwen M.
    Nanda, Rita
    Olopade, Olufunmilayo I.
    Huo, Dezheng
    CANCER RESEARCH, 2023, 83 (05)
  • [46] Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low
    Hu, Xi'e
    Yang, Ping
    Chen, Songhao
    Wei, Gang
    Yuan, Lijuan
    Yang, Zhenyu
    Gong, Li
    He, Li
    Yang, Lin
    Peng, Shujia
    Dong, Yanming
    He, Xianli
    Bao, Guoqiang
    BREAST CANCER RESEARCH, 2023, 25 (01)
  • [47] Heterogeneity and prognostic characteristics of HER2-low breast cancer: A retrospective analysis of patients with HER2-negative metastatic breast cancer
    Lv, Huimin
    Yan, Min
    Zhang, Mengwei
    Niu, Limin
    Zeng, Huiai
    Sun, Huihui
    Zhao, Shengnan
    Wang, Jing
    CANCER RESEARCH, 2024, 84 (09)
  • [48] Impact of HER2 status (HER2-low versus HER2-0) on complete histologic response after neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC)
    Domergue, C.
    Martin, E.
    Lemarie, C.
    Jezequel, P.
    Frenel, J-S.
    Augereau, P.
    Campone, M.
    Patsouris, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S428 - S429
  • [49] HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
    van den Ende, Nadine S.
    Smid, Marcel
    Timmermans, Annemieke
    van Brakel, Johannes B.
    Hansum, Tim
    Foekens, Renee
    Trapman, Anita M. A. C.
    Heemskerk-Gerritsen, Bernadette A. M.
    Jager, Agnes
    Martens, John W. M.
    van Deurzen, Carolien H. M.
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [50] The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
    Wang, Wei
    Zhu, Tingting
    Chen, Hao
    Yao, Yongzhong
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (06) : 1673 - 1681
12345